Siddique Aurangzeb, Shantsila Eduard, Lip Gregory Yh, Varma Chetan
Haemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
Department of Cardiology, City Hospital, Birmingham, UK.
J Angiogenes Res. 2010 Feb 22;2:6. doi: 10.1186/2040-2384-2-6.
Endothelial Progenitor Cells (EPC) were first described in 1997 and have since been the subject of numerous investigative studies exploring the potential of these cells in the process of cardiovascular damage and repair. Whilst their exact definition and mechanism of action remains unclear, they are directly influenced by different cardiovascular risk factors and have a definite role to play in defining cardiovascular risk. Furthermore, EPCs may have important therapeutic implications and further understanding of their pathophysiology has enabled us to explore new possibilities in the management of cardiovascular disease. This review article aims to provide an overview of the vast literature on EPCs in relation to clinical cardiology.
内皮祖细胞（EPC）于1997年首次被描述，自那时起便成为众多研究的主题，这些研究探索了这些细胞在心血管损伤和修复过程中的潜力。虽然它们的确切定义和作用机制仍不清楚，但它们受到不同心血管危险因素的直接影响，并且在确定心血管风险方面具有明确作用。此外，内皮祖细胞可能具有重要的治疗意义，对其病理生理学的进一步了解使我们能够探索心血管疾病管理的新可能性。这篇综述文章旨在概述与临床心脏病学相关的关于内皮祖细胞的大量文献。
